Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 70/100

Radiopharm receives $1.9 M advance on FY24 R&D tax incentive

Wednesday, February 21, 2024 1 min read
Key Takeaway: Radiopharm Theranostics has secured a $1.9 million advance related to its R&D tax incentive for the fiscal year 2024. This funding is expected to bolster the company's research efforts and support ongoing projects. The advance reflects confidence in Radiopharm's innovative capabilities and future potential.

Market Sentiment Analysis

POSITIVE FACTORS

  • Radiopharm receives a significant $1.9 million advance.
  • The funding is related to R&D tax incentives for FY24.
  • Positive financial support can enhance future research initiatives.

Full Press Release Details

• Announcements
• Periodic Reports , Price Sensitive
• February 21, 2024
Loading Viewer…

More Announcements & Updates

• Announcements
• February 21, 2024
• Announcements
• December 9, 2022
• Announcements
• March 7, 2025
• Announcements
• September 16, 2022

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What amount did Radiopharm receive for R&D?

Radiopharm received a $1.9 million advance related to its R&D tax incentive.

What is the purpose of the $1.9 million advance?

The advance is intended to support Radiopharm's research initiatives for FY24.

How does this funding impact Radiopharm?

This funding is expected to enhance Radiopharm's research capabilities and ongoing projects.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm RDX R&D tax incentive clinical study funding
Last updated: Feb 21, 2024